Skip to content

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

David F Cella, David S. Tulsky, Geoffrey V. Gray, Bernie Sarafian, Eric Linn, Amy E. Bonomi, Margaret A. Silberman, S B Yellen, Patsy Winicour, J Brannon

Journal of Clinical Oncology · 1993 · 6,082 citations

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Cella, D. F., Tulsky, D. S., Gray, G. V., Sarafian, B., Linn, E., Bonomi, A. E., Silberman, M. A., Yellen, S. B., Winicour, P., & Brannon, J. (1993). The functional assessment of cancer therapy scale: development and validation of the general measure. Journal of Clinical Oncology, 11(3), 570–579. https://doi.org/10.1200/jco.1993.11.3.570

In text: (Cella et al., 1993)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

PURPOSE: We developed and validated a brief, yet sensitive, 33-item general cancer quality-of-life (QL) measure for evaluating patients receiving cancer treatment, called the Functional Assessment of Cancer Therapy (FACT) scale. METHODS AND RESULTS: The five-phase validation process involved 854 patients with cancer and 15 oncology specialists. The initial pool of 370 overlapping items for breast, lung, and colorectal cancer was generated by open-ended interview with patients experienced with the symptoms of cancer and oncology professionals. Using preselected criteria, items were reduced to a 38-item general version. Factor and scaling analyses of these 38 items on 545 patients with mixed cancer diagnoses resulted in the 28-item FACT-general (FACT-G, version 2). In addition to a total score, this version produces subscale scores for physical, functional, social, and emotional well-being, as well as satisfaction with the treatment relationship. Coefficients of reliability and validity were uniformly high. The scale's ability to discriminate patients on the basis of stage of disease, performance status rating (PSR), and hospitalization status supports its sensitivity. It has also demonstrated sensitivity to change over time. Finally, the validity of measuring separate areas, or dimensions, of QL was supported by the differential responsiveness of subscales when applied to groups known to differ along the dimensions of physical, functional, social, and emotional well-being. CONCLUSION: The FACT-G meets or exceeds all requirements for use in oncology clinical trials, including ease of administration, brevity, reliability, validity, and responsiveness to clinical change. Selecting it for a clinical trial adds the capability to assess the relative weight of various aspects of QL from the patient's perspective.

  1. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology1993
  2. Cochrane Handbook for Systematic Reviews of Interventions2019
  3. PedsQL™ 4.0: Reliability and Validity of the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales in Healthy and Patient Populations2001

Metadata from OpenAlex (CC0). Citations are generated from the published record.